By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroDerm Ltd. 

Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209



Company News
NeuroDerm (NDRM) Provides Updates On ND0612 Long-Term Safety Trial And Submission Of Marketing Applications 9/29/2016 11:43:54 AM
NeuroDerm (NDRM)’s ND0612 Mini-Pump Delivery System Successfully Used By Parkinson’s Disease Patients In Home Setting 9/23/2016 8:02:44 AM
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016 8:32:22 AM
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016 7:56:30 AM
NeuroDerm (NDRM) Announces Second Quarter 2016 Financial Results And Provides Corporate Update 8/25/2016 7:55:47 AM
NeuroDerm (NDRM) To Host Second Quarter 2016 Financial Results Conference Call On August 25, 2016 8/11/2016 11:23:49 AM
NeuroDerm (NDRM) Announces Issuance Of A New U.S. Patent For Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions 7/27/2016 8:47:33 AM
NeuroDerm (NDRM) Announces Start Of Bioequivalence Trial In Healthy Volunteers Of ND0701, A New Continuous Subcutaneously Delivered Apomorphine Product Candidate For The Treatment Of Advanced Parkinson’s Disease 7/26/2016 8:38:14 AM
NeuroDerm (NDRM) To Present At The Cantor Fitzgerald Healthcare Conference On July 13 7/5/2016 8:47:23 AM
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016 12:12:35 PM